首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Esmo open

缩写:

ISSN:N/A

e-ISSN:2059-7029

IF/分区:8.3/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引2013
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
M H Derbala,J Hajjar,B Stephen et al. M H Derbala et al.
Background: Immune checkpoint inhibitors (ICIs) have limited response rates in selected patients and can cause potentially life-threatening immune-related adverse events (irAEs). This underscores the urgent need for the d...
D Melisi,T Macarulla,C De La Fouchardière et al. D Melisi et al.
Background: In NAPOLI 3 (NCT04083235), first-line (1L) liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) demonstrated statistically significant improvements in overall survival and progressi...
C Lemaire,A Boileve,G Manceau et al. C Lemaire et al.
Background: Several studies showed that in mismatch repair-deficient (dMMR)/microsatellite instability (MSI) nonmetastatic colon cancer (CC), neoadjuvant immune checkpoint inhibitors (ICIs) were associated with exceptiona...
H Yoon,H Jeong,I Park et al. H Yoon et al.
Background: MDM2, a negative regulator of p53, has emerged as a potential therapeutic target as its inhibition can restore p53 tumor suppressor activity in MDM2-amplified tumors, including subsets of biliary tract cancer ...
E Rosenbaum,K Seier,M Bradic et al. E Rosenbaum et al.
Background: Sarcomas are frequently infiltrated with immunosuppressive myeloid cells. Vimseltinib is an inhibitor of the colony-stimulating factor 1 receptor kinase and has been shown to decrease tumor-infiltrating myeloi...
K Nozawa,H Iwata,T Mukohara et al. K Nozawa et al.
Background: Trastuzumab deruxtecan (T-DXd) is recommended in the second-line or later setting for patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer (mBC). However...
L Gui,Z Xie,W Zhang et al. L Gui et al.
Introduction: Hypopharyngeal squamous cell carcinoma (HPSCC) has the poorest prognosis among head and neck cancer subtypes. The efficacy, role in organ preservation, safety, and biomarkers of induction immunochemotherapy ...
R Jeselsohn,J Fu,Y Ren et al. R Jeselsohn et al.
Background: Genomic determinants of response and resistance to endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) beyond progression in hormone receptor-positive/human epidermal growth factor rece...
K S Shohdy,L Kassem,T Elnahas et al. K S Shohdy et al.
Background: There is a lack of studies investigating the burden of BRCA1/2 pathogenic variants (PVs) in Northern African countries using next-generation sequencing (NGS)-based testing in patients with epithelial ovarian (...
C Corti,X Chu,P Exman et al. C Corti et al.
Background: The 50-gene assay Prosigna is cleared by the United States Food and Drug Administration only in postoperative hormone receptor-positive (HR-positive) breast cancer (BC) specimens. Given studies showing that Pr...